The role for interleukin-12 therapy of cutaneous T cell lymphoma.

Published

Journal Article

Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.

Full Text

Duke Authors

Cited Authors

  • Rook, AH; Zaki, MH; Wysocka, M; Wood, GS; Duvic, M; Showe, LC; Foss, F; Shapiro, M; Kuzel, TM; Olsen, EA; Vonderheid, EC; Laliberte, R; Sherman, ML

Published Date

  • September 2001

Published In

Volume / Issue

  • 941 /

Start / End Page

  • 177 - 184

PubMed ID

  • 11594571

Pubmed Central ID

  • 11594571

International Standard Serial Number (ISSN)

  • 0077-8923

Digital Object Identifier (DOI)

  • 10.1111/j.1749-6632.2001.tb03721.x

Language

  • eng

Conference Location

  • United States